Clinical Trials Browser

Phase 1/2 × Inotuzumab Ozogamicin × Myeloid × Clear all

NCT02311998 2023-07-17

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

Phase 1/2 Completed

22 enrolled 14 charts

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive